Avantor increases manufacturing of single-use technology

By The Science Advisory Board staff writers

April 27, 2021 -- Avantor plans to increase its manufacturing capability of single-use technologies for biologics and vaccines.

The company will increase its capacity in the U.S. and Europe by 30% and double its cleanroom space to support demand for monoclonal antibodies, cell and gene therapies for oncology, and vaccines, including those for COVID-19.

The firm has already expanded its facility in Morrisville, NC, and will expand another in Devens, MA, by mid-year. It also plans to open a second European single-use technology manufacturing site, in Hillegom, the Netherlands.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.